{"url_path":"/sec/cero/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1870404/0001213900-26-057753-index.html","accession_number":"0001213900-26-057753","cik":"0001870404","ticker":"CERO","issuer_name":"CERO THERAPEUTICS HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1870404/0001213900-26-057753-index.html","primary_entity_key":"0001870404","primary_entity_name":"CERO THERAPEUTICS HOLDINGS, INC."},"word_count":468,"has_tables":true,"body_markdown":"**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n**(Mark\nOne)**\n\n☒\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n☐\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from          to         **   \n\n \n\n**Commission\nFile No. 001-40877**\n\n \n\n**CERO\nTHERAPEUTICS HOLDINGS, INC.**\n\n**(Exact\nname of registrant as specified in its charter)**\n\n \n\n**Delaware**   **81-4182129**\n\n**(State or other jurisdiction of incorporation or organization)**   **(I.R.S. Employer Identification No.)**\n\n \n\n**201\nHaskins Way, Suite 230, South San Francisco, CA 94080**\n\n**(Address\nof Principal Executive Offices, including zip code)**\n\n \n\n**(650)\n407-2376**\n\n**(Registrant’s\ntelephone number, including area code)**\n\n \n\n**N/A**\n\n**(Former\nname, former address and former fiscal year, if changed since last report)**\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act:**\n\n \n\n**Title of each class**   **Trading Symbol(s)**   **Name of each exchange on which registered**\n\nCommon Stock, par value $0.0001 per share   CERO   None\n\nWarrants, each warrant exercisable for one two-thousandths of a share of Common Stock   CEROW   None\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was\nrequired to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐ Accelerated filer ☐\n\nNon-accelerated filer ☒ Smaller reporting company ☒\n\n    Emerging growth company ☒\n\n** **\n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒\n\n \n\nAs\nof May 14, 2026 there were 45,112,406 shares of Common Stock, par value $0.0001 per share, issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n**CERO\nTHERAPEUTICS HOLDINGS, INC.**\n\n**FORM\n10-Q**\n\n**FOR\nTHE QUARTER ENDED MARCH 31, 2026**\n\n \n\n**TABLE\nOF CONTENTS**\n\n \n\n \n \n**Page**\n\n**PART\n1 - FINANCIAL INFORMATION**\n1"}